Standard BioTools (LAB) Competitors $1.30 -0.03 (-2.26%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.30 -0.01 (-0.38%) As of 08/1/2025 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LAB vs. TXG, TRNS, EYPT, ALNT, AEHR, CTKB, QSI, SENS, QTRX, and FEIMShould you be buying Standard BioTools stock or one of its competitors? The main competitors of Standard BioTools include 10x Genomics (TXG), Transcat (TRNS), EYEPOINT PHARMACEUTICALS (EYPT), Allient (ALNT), Aehr Test Systems (AEHR), Cytek Biosciences (CTKB), Quantum-Si (QSI), Senseonics (SENS), Quanterix (QTRX), and Frequency Electronics (FEIM). These companies are all part of the "measuring and control equipment" industry. Standard BioTools vs. Its Competitors 10x Genomics Transcat EYEPOINT PHARMACEUTICALS Allient Aehr Test Systems Cytek Biosciences Quantum-Si Senseonics Quanterix Frequency Electronics 10x Genomics (NASDAQ:TXG) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership. Which has better valuation and earnings, TXG or LAB? Standard BioTools has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$610.78M2.64-$182.63M-$1.30-10.06Standard BioTools$174.43M2.83-$138.88M-$0.35-3.71 Is TXG or LAB more profitable? 10x Genomics has a net margin of -25.14% compared to Standard BioTools' net margin of -78.24%. Standard BioTools' return on equity of -22.44% beat 10x Genomics' return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-25.14% -23.22% -18.02% Standard BioTools -78.24%-22.44%-16.74% Does the media refer more to TXG or LAB? In the previous week, 10x Genomics had 5 more articles in the media than Standard BioTools. MarketBeat recorded 10 mentions for 10x Genomics and 5 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.45 beat 10x Genomics' score of 0.72 indicating that Standard BioTools is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Standard BioTools 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, TXG or LAB? 10x Genomics has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Do analysts prefer TXG or LAB? 10x Genomics currently has a consensus price target of $13.23, indicating a potential upside of 1.13%. Standard BioTools has a consensus price target of $2.50, indicating a potential upside of 92.31%. Given Standard BioTools' stronger consensus rating and higher probable upside, analysts clearly believe Standard BioTools is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 1 Sell rating(s) 5 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.42Standard BioTools 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in TXG or LAB? 84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 9.4% of 10x Genomics shares are held by company insiders. Comparatively, 23.2% of Standard BioTools shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryStandard BioTools beats 10x Genomics on 11 of the 17 factors compared between the two stocks. Get Standard BioTools News Delivered to You Automatically Sign up to receive the latest news and ratings for LAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LAB vs. The Competition Export to ExcelMetricStandard BioToolsMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$505.16M$2.04B$5.49B$9.54BDividend YieldN/AN/A4.73%4.09%P/E Ratio-3.7133.7928.8323.83Price / Sales2.8328.84372.0766.02Price / CashN/A56.2135.4557.96Price / Book1.028.978.275.54Net Income-$138.88M-$62.31M$3.25B$259.28M7 Day Performance-7.14%-8.15%-3.73%-4.68%1 Month Performance-5.11%1.83%4.29%4.36%1 Year Performance-21.21%21.01%25.87%17.88% Standard BioTools Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LABStandard BioTools3.3857 of 5 stars$1.30-2.3%$2.50+92.3%-8.5%$505.16M$174.43M-3.71620News CoveragePositive NewsGap DownTXG10x Genomics3.7695 of 5 stars$14.64+3.8%$13.23-9.6%-33.5%$1.74B$610.78M-11.261,240News CoverageUpcoming EarningsAnalyst ForecastShort Interest ↑Gap DownTRNSTranscat3.3122 of 5 stars$82.71-1.7%$112.20+35.7%-32.9%$784.08M$278.42M53.021,245Upcoming EarningsEYPTEYEPOINT PHARMACEUTICALS1.9021 of 5 stars$10.03-4.3%$25.67+155.9%+6.4%$721.14M$43.27M-4.16120News CoverageUpcoming EarningsALNTAllient2.3064 of 5 stars$39.91+0.4%$31.00-22.3%+38.5%$672.75M$529.97M67.652,525News CoveragePositive NewsUpcoming EarningsGap DownAEHRAehr Test Systems1.6485 of 5 stars$20.91-3.8%N/A+1.8%$647.23M$58.97M-160.8390Gap DownCTKBCytek Biosciences2.344 of 5 stars$3.75+1.6%$5.60+49.3%-43.2%$467.37M$200.45M-41.66500Positive NewsUpcoming EarningsQSIQuantum-Si2.5321 of 5 stars$1.79-7.3%$3.48+94.1%+47.6%$354.15M$3.06M-2.63150Upcoming EarningsGap DownSENSSenseonics1.6234 of 5 stars$0.54-2.2%$1.55+187.0%+21.1%$353.34M$23.68M-4.1590QTRXQuanterix2.2462 of 5 stars$6.49+10.9%$13.50+108.0%-58.3%$292.23M$137.42M-4.99460Upcoming EarningsGap DownFEIMFrequency Electronics1.0606 of 5 stars$27.87-0.4%N/A+99.3%$272.19M$69.81M11.28200Short Interest ↑Gap Down Related Companies and Tools Related Companies 10x Genomics Alternatives Transcat Alternatives EYEPOINT PHARMACEUTICALS Alternatives Allient Alternatives Aehr Test Systems Alternatives Cytek Biosciences Alternatives Quantum-Si Alternatives Senseonics Alternatives Quanterix Alternatives Frequency Electronics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LAB) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Standard BioTools Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Standard BioTools With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LAB Stock Alerts